Responses
Clinical and epidemiological research
Concise report
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 13 April 2016
- Published on: 13 April 2016SF-36 improves in a 6-week RA trial: so what?Show More
Dear Editor,
Dear editor,
I was disappointed in the publication of the concise report on the effects of an orally active Janus kinase (JAK) inhibitor on patient-reported outcomes in rheumatoid arthritis (RA). [1] JAK inhibition represents a new treatment option with potential in RA, so the results of the proof-of-concept trial were of interest, even though it lasted only 6 weeks; and these were duly published.[...
Conflict of Interest:
None declared.